FDA Brief

Warning letters Food

FDA warning letter to

Anabolic Laboratories Inc

LowIssued Nov 14, 2022Posted Nov 17, 2022Center for Food Safety and Applied Nutrition (CFSAN)

FDA told Anabolic Laboratories its CoQ10 Ubiquinol Prime and Policosanol Microtabs supplements were unapproved new drugs because website claims promised disease treatment.

What happened

In August 2022, FDA reviewed Anabolic Laboratories' website and determined that the company takes orders there for CoQ10 Ubiquinol Prime and Policosanol Microtabs. FDA found website claims that the products are intended to treat diseases and conditions such as heart failure and high cholesterol. FDA says those claims make the products drugs, and that they are unapproved new drugs and misbranded.

What FDA found

  1. FDA says the website claims make CoQ10 Ubiquinol Prime and Policosanol Microtabs intended to cure, mitigate, treat, or prevent disease, so they are drugs under the Act.

    Section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. FDA says these products are not generally recognized as safe and effective for those uses, making them unapproved new drugs.

    Section 201(p) [21 U.S.C. 321(p)]
  3. FDA says a new drug cannot be introduced into interstate commerce without prior FDA approval.

    Sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  4. FDA says CoQ10 Ubiquinol Prime is misbranded because it lacks adequate directions for use by a layperson.

    Section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  5. FDA says introducing the misbranded drug into interstate commerce violates the Act.

    Section 301(a) [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, FDA asks Anabolic Laboratories to notify it in writing of the specific steps taken to address the matters and prevent recurrence, with related documentation. If corrections cannot be completed in that time, FDA asks the company to explain the delay and state when corrections will be completed.

Who should pay attention

  • dietary supplement brands making disease-treatment claims online
  • contract manufacturers or distributors of CoQ10 and policosanol products
  • regulatory reviewers of supplement websites and label claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk